Long Term Prognostic of Neonatal Hypoxic Ischemic Encephalopathy With Hypothermia Treatment (LyTONEPAL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02676063|
Recruitment Status : Active, not recruiting
First Posted : February 8, 2016
Last Update Posted : June 6, 2018
The primary objective is to evaluate neonatal characteristics, and biological and clinical investigations as predictive factors of death, or of severe and moderate neurodevelopmental disability at 3 years, in a large population-based cohort of full-term and late preterm neonates with moderate or severe HIE.
Contrary to most previous studies which have often analyzed the accuracy of one factor among all other clinical investigations, the investigators objective's is to seek a relevant combination of several factors among the following list:
- Neonatal characteristics: gestational age and birthweight, maternal disease, acute intrapartum event, delivery mode, acidosis, neurological examination, place of birth and neonatal transfer
- Laboratory investigations: pH, lactates and new biological markers as detailed below
- Clinical investigations: aEEG, EEG, MRI, diffusion-weighted MRI
|Condition or disease|
Hypoxic-ischemic encephalopathy (HIE) is a rare neonatal condition affecting about 1‰ births and with a high rate of death and severe neurological disability despite significant improvement of the management of this illness in the last ten years. During the first hours and days of life, different examinations are made by neonatologists to guide decisions about the management of HIE and to provide information to families. Nevertheless, better knowledge about the early and late predictive factors of long-term severe and moderate neurodevelopmental outcomes is badly needed.
This study is a prospective national observational population-based study involving all level III intensive care units in France.
This population-based cohort study will be performed including all moderate or severe cases of HIE, occurring between 34 and 42 completed weeks gestation in newborns admitted to a neonatal intensive care unit of the participating French regions. Children will be followed-up until the age of 3 years.
Participating centers will be invited to adhere to current HIE management guidelines and/or clinical investigations considered optimal to date, to ensure standardize clinical practice. The study will ensure high quality data collection.
About indications, timing and characteristics of treatments and investigations will be elaborated by the scientific committee during the preparation stage of the cohort study. This professional advice will have the double advantage of enabling us to record more homogeneous and high-quality data, and to standardize and improve clinical management and investigations among newborns with HIE.
Within this main study, an ancillary study will be performed by 21 centers to address the first secondary objective (predictive value of very early - first 6 hours of life - neurological examination and biological investigations, including specific new biomarkers such as Interleukin-6, Metalloproteinase-9, TIMP-1, Albumin modified by hypoxia, troponin I, acylcarnitins and amino acids).
|Study Type :||Observational|
|Estimated Enrollment :||800 participants|
|Official Title:||Long Term Prognostic of Neonatal Hypoxic Ischemic Encephalopathy in the Era of Neuroprotective Treatment With Hypothermia|
|Actual Study Start Date :||September 2015|
|Estimated Primary Completion Date :||March 2019|
|Estimated Study Completion Date :||March 2021|
neonatal Hypoxic Ischemic encephalopathy
moderate or severe HIE among term and late preterm newborn
- The primary outcome measure is a combined criterion : death, neurodevelopmental disabilities in survivors [ Time Frame: between birth and 3 years of age ]
A combined criterion which includes:
- Death between birth and 3 years of age
Neurodevelopmental disabilities in survivors, defined as :
o Severe disabilities
- Intellectual impairment with a mental score >2SD below the mean or <70 (ASQ)
- Or Cerebral palsy with a Gross Motor Function level of 3-5 according to the GMFCS
- Or bilateral blindness (vision <20/200 acuity)
- Or deafness requiring amplification (>60dB)and/
Or a persistent disorder defined as recurrent seizures after discharge from neonatal intensive care requiring anti-convulsion therapy at the examination time point
o Moderate disabilities
- Intellectual impairment with a mental score >1SD below the mean or 70 to 84 (ASQ)
- Cerebral palsy with a Gross Motor Function level of 1 or 2 according to the GMFCS
- Or hearing impairment requiring no amplification
- First secondary objective : The relevance of specific new biomarkers : Protein levels (IL-6, MMP-9, TIMP-1, Albumine modified by hypoxia, troponine I), acylcarnitins and amino acids. [ Time Frame: before H6 and at 3 days ]
The biologist will evaluate the relevance of specific new biomarkers :
- Protein levels (IL-6, MMP-9, TIMP-1, Albumine modified by hypoxia, troponine I) unites will be determined using an ELISA
- the measurement of acylcarnitins and amino acids by tandem liquid phase chromatography coupled with mass spectroscopy.
The analyses will be blinded and centralized to Reims University laboratory
- Second secondary objective: the predictive value of clinical investigations during the first weeks of life and treatments. [ Time Frame: first week, At 18 months and 3 years of age ]
To analyze the predictive value of clinical investigations during the first weeks of life and treatments, including cooling:
- for normal outcomes (absence of death, any disability, any epilepsy or any need for physiotherapy, orthophonist or psychologist or other measures of reeducation), moderate or severe neurodevelopmental disabilities, and death
- At 18 months and 3 years of age
- In this part, we will assess the ability of a normal developmental assessment at 18 months to predict survival free of disability or retardation at 3 years. This information will be useful in the future to define different strategies of follow up according to the assessment at 18 months of age.
- Third secondary objective : Number and percentage of participants with cooling. [ Time Frame: birth ]
The third secondary objective is analyzed thanks to :
- number of patients with method of cooling : Criticool, tecotherm, craft, other
- duration of cooling in hours
- number of severe or modere HIE according to the Sarnat classification
- time to initiate cooling in minutes
- Fourth secondary objective : Number and percentage of various obstetrical conditions leading to the worse outcomes [ Time Frame: birth ]
Number and percentage of :
- Maternal pyrexia,
- a persistent occipito-posterior position,
- an acute intrapartum event (hemorrhage, maternal convulsions, rupture of uterus, snapped cord, and birth of baby before arrival at obstetric facility),
- an instrumental vaginal delivery
- an emergency caesarean section
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02676063
|Principal Investigator:||Thierry DEBILLON, MD PhD||University Hospital, Grenoble|